Compare Amgen, Inc. (AMGN) vs Marqeta Inc (MQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Marqeta Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Marqeta Inc trades at $15.8 (market cap $1.67B). The key difference: Amgen, Inc. is far larger — about 117.4× Marqeta Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| AMGN | MQ | |
|---|---|---|
Market Cap | $196.12B | $1.67B |
Sector | Health | Technology |
52-Week High | $388.16 | $27.32 |
52-Week Low | $271.18 | $15.04 |
Enterprise Value | $241.41B | $972.59M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MQ trades at $15.87, up 2.32% today, with a bearish technical signal and neutral oscillators. Revenue has improved from $507M in 2024 to $625M in 2025, though net income remains negative. The company recently announced a 4:1 reverse stock split effective July 1, 2026, and will report Q2 2026 earnings on August 4, 2026. Analyst consensus is a buy rating with a $19.00 price target, indicating potential upside from current levels.
MQ shows revenue growth and expanding European presence, but profitability is weak with a high P/E of 396.75. Risks include ongoing net losses, competitive fintech pressures, and shareholder litigation. The stock offers speculative growth potential if execution improves, but investors face significant fundamental and sentiment headwinds near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
